Research Paper Volume 13, Issue 10 pp 14015—14038
NUPR1 is a novel potential biomarker and confers resistance to sorafenib in clear cell renal cell carcinoma by increasing stemness and targeting the PTEN/AKT/mTOR pathway
Figure 6. NUPR1 silencing mediated stem-like properties and suppressed the PTEN/AKT/mTOR signaling pathway in ccRCC. (A) Western blot analysis of effects of NUPR1 depletion on stemness-related biomarkers. (B) Tumor sphere assay was used for analysis of cancer stemness for NUPR1 silencing. (C) knockdown of NUPR1 increased PTEN and decreased the protein levels of p-mTOR, p-AKT, p-S6K and p-4EBP1 in ccRCC cells. (*p < 0.05, **p < 0.01, ***p < 0.001).